Equities
Health CareMedical Equipment and Services
  • Price (HKD)5.11
  • Today's Change-0.09 / -1.73%
  • Shares traded4.86m
  • 1 Year change+3.02%
  • Beta0.6583
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shandong Weigao Group Medical Polymer Co Ltd is a China-based company principally engaged in the research and development, production and sale of medical device products. The Company operates its businesses through six segments. The Medical Device segment produces and sells clinical care, medical testing, anesthesia and surgical related products and other consumables. The Orthopaedic Products segment produces and sells orthopaedic products, including tissue repair product line. The Interventional Products segment produces and sells tumour and blood vessel interventional instruments. The Pharma Packaging Products segment produces and sells pre-filled syringes and flushing syringes. The Blood Management Products segment produces and sells blood collection, irradiation, storage, separation and sterilization products. The Others segment engages in finance lease and factoring business. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)14.82bn
  • Net income in HKD2.23bn
  • Incorporated2000
  • Employees13.06k
  • Location
    Shandong Weigao Group Medical Polymer Co Ltd1 Weigao RoadTorch Hi-tech Science ParkWEIHAI 264210ChinaCHN
  • Phone+86 6 315621999
  • Fax+86 6 315621999
  • Websitehttps://www.weigaoholding.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Oshidori International Holdings Ltd36.69m12.14m8.22bn23.00678.572.59384.34224.160.0020.0020.00590.51420.011--0.311,595,044.000.3577-2.150.376-2.31----32.58------0.0242---40.14-33.74-130.22---45.42--
Sun Hung Kai & Co Ltd3.91bn1.19bn8.63bn942.007.230.39215.512.210.60680.60681.9911.200.1013--0.42663,997,239.003.632.515.183.5297.1897.2535.8226.49----0.309170.806.51-5.12180.12-28.94-4.430.00
Allied Group Ltd16.19bn1.13bn11.52bn6.06k10.220.25824.330.71190.32090.32094.6112.700.14430.466717.562,814,971.002.051.973.843.5163.4369.8914.1825.301.123.010.213726.6115.422.99-519.38--27.55--
Qfin Holdings Inc22.17bn7.79bn15.82bn3.53k2.190.5845--0.713728.1228.1280.14105.400.3614--9.386,285,109.0012.6713.3418.7923.7084.7485.3035.0729.65----0.2066--5.3813.2446.1820.1546.24--
Yixin Group Ltd12.30bn1.07bn17.65bn4.54k16.520.956513.531.430.15740.15741.812.720.2283--3.372,875,070.001.990.34823.270.550649.6149.338.732.13--12.470.6362192.8047.8911.2645.9592.13-13.42--
Shandong Weigao Group Medical Polymer Co14.82bn2.23bn23.14bn13.06k10.480.8556.681.560.48750.48753.245.980.37052.872.051,164,794.005.857.587.389.8349.6952.8115.7818.243.3216.680.176633.39-1.084.743.242.24-8.0513.11
Data as of Feb 16 2026. Currency figures normalised to Shandong Weigao Group Medical Polymer Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

18.92%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 22 May 2025190.61m4.22%
Norges Bank Investment Managementas of 30 Jun 2025150.68m3.33%
BlackRock Fund Advisorsas of 29 Jan 2026111.44m2.46%
The Vanguard Group, Inc.as of 04 Feb 2026100.02m2.21%
Fidelity Management & Research Co. LLCas of 31 Dec 202570.51m1.56%
ARGA Investment Management LPas of 31 Oct 202560.62m1.34%
Dimensional Fund Advisors LPas of 05 Feb 202646.42m1.03%
State Street Global Advisors Ltd.as of 05 Feb 202645.18m1.00%
Schroder Investment Management (Hong Kong) Ltd.as of 31 Dec 202540.48m0.90%
BlackRock Financial Management, Inc.as of 29 Jan 202639.89m0.88%
More ▼
Data from 30 Sep 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.